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Diagnosis and treatment of cancer 
breakthrough pain in opinions of 
physicians working in Outpatients’ 
Palliative Care Units and Pain 
Clinics
Abstract
Breakthrough pain (BtP) is common among patients suffering from cancer pain. The experience, knowledge 
and education of palliative care physicians or pain management specialists seem to be essential for proper 
diagnosis and treatment of breakthrough pain. The purpose of this study was to determine the scope and 
assess the knowledge of physicians regarding BtP and its management. 135 physicians have participated in 
the study and completed special questionnaires for the period from April to July 2010. The vast majority of 
surveyed physicians (133 out of 135) declared that they diagnosed the BtP in their patients, usually 2 to 3 
episodes a day. The time for the pain to become maximal, in the opinion of 73% of physicians, was usually 
between 5 to 30 minutes, the average duration of the breakthrough pain episode approximately was 15–
–30 minutes. The vast majority of respondents prescribed pharmacological treatment to manage the BtP 
episodes, most commonly morphine, non-steroidal anti-inflammatory drugs, acetaminophen and tramadol. 
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Introduction
Available data indicates that there are approxi-
mately 25 million people with cancer in the world 
today. 30–40 percent of the patients experience 
pain even at the time of diagnosis, and this number 
is definitely increasing as the disease progresses. At 
the end of life, up to 70–90 percent of patients suffer 
from pain [1]. Breakthrough pain (BtP) is a common 
phenomenon among the population of patients with 
cancer pain. It is estimated that it is present in 
40–80% of patients in this group [2]. Breakthrough 
pain is defined as a tran-sient exacerbation of pain, 
which can occur either spontaneously or under 
the influence of a specific stimulus, either predict-
able or unpredictable, despite relatively stable and 
well-controlled background pain. Short-acting opi-
oids, referred to as the rescue medication, are usually 
used as the therapy, in addition to analgesics given in 
the around-the-clock regimen [3]. Although BtP is not 
a rare phenomenon, its diagnosis and treatment still 
leaves much to be desired. Hence, it appears that 
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the basic and essential element in determining the 
appropriate treatment of breakthrough pain is the 
education and knowledge of physicians working in 
outpatients’ pain clinics and palliative care units. 
The aim of this study was to determine the extent of 
education of physicians working in outpatients’ pain 
clinics and palliative care units in Poland, regarding 
breakthrough pain and its treatment.
Methods
135 physicians, who are working in outpatients’ 
pain clinics and palliative care units (34 and 11 re-
spectively) on Polish territory, participated in the 
study.
The questionnaire developed for the study, which 
was used to perform the survey, contained 12 ques-
tions. Percentage values were used for the analysis of 
the responses given by the participating physicians. 
Charts and tables have been drawn by means of 
graphic software.
Results
The questionnaire has been completed and re-
turned by 135 physicians who treated patients suffer-
ing from cancer pain. Apart from the cancer, another 
significant problem, according to the respondents, 
was pain caused by cancer treatment: surgery, radia-
tion therapy and chemotherapy (responses given by 
17.8%, 16.3% and 11.1% of physicians, respectively) 
and also due to co-morbidities, as selected by 8.15% 
physicians. None of the respondents indicated pain 
of unknown origin. Most of the surveyed physi-
cians (76.3%) declared that they diagnosed mixed 
pain (nociceptive and neuropathic). 9.6% of the 
physicians observed in their patients somatic noci-
ceptive pain only, and 21.5% of the physicians re-
corded the occurrence of visceral pain. One in six 
respondents declared the presence of neuropathic 
pain in their patients. When asked about the choice 
of drugs they used to treat cancer pain, the re-
spondents most often indicated morphine (96% 
of physicians), fentanyl (78%), and non-steroidal 
anti-inflammatory drugs (73%). Nearly as many of 
them declared that they prescribed tramadol (2/3 of 
physicians) and acetaminophen (61%). Methadone 
(3.7%) and oxycodone (0.74% — prescribed by one 
person only) were used very rarely, as during the 
study period the reimbursement status of these 
drugs limited their availability to patients (Table 1). 
The vast majority of the participating physi-
cians (133 out of 135 — 98.32%) declared that they 
diagnosed breakthrough pain in their patients. Only 
one medical practitioner (0.74%) reported that he 
or she did not recognize episodes of breakthrough 
pain, and one person did not answer this question. 
Despite the explicit requests to respond to no further 
questions, both respondents continued to fill out 
the questionnaire. 
According to the responses of the participating 
physicians, the etiology of breakthrough pain is usu-
ally only associated with the underlying disease, 
as indicated by two thirds of the respondents. One 
in three doctors indicated underlying disease and 
its treatment as the cause, and only 8% of physi-
cians indicated a relationship between breakthrough 
pain and the treatment of the underlying disease. 
The kind of breakthrough pain that was most 
frequently indicated by physicians was mixed pain 
(according to 57.8% of respondents), followed by no-
ciceptive pain (34.8%) and neuropathic pain (17.8%). 
A half of the physicians (50.4%) selected the oc-
currence of spontaneous breakthrough pain. 34% of 
the respondents defined breakthrough pain as inci-
dental and unrelated to the patients’ actions. One 
in five doctors (20.74%) declared that breakthrough 
pain was incidental and related to the patients’ ac-
tions. According to 43% of doctors, patients experi-
enced an average of two episodes of breakthrough 
pain a day. 37.8% of physicians reported an aver-
age of 3 episodes of breakthrough pain a day. At 
the same time, ten medical practitioners (7.41%) 
diagnosed 4, and four (2.96%) diagnosed more 
than 4 episodes of breakthrough pain per day (Ta-
ble 2). Nearly a half of the physicians (45.9%) said 
that the average time for the breakthrough pain 
to reach maximum intensity was 5 to 15 minutes. 
Table 1. Drugs prescribed by physicians to control 
background pain (more than one answer was 
possible) 
Analgesic used Number of 
answers
% of answers
Paracetamol 82 61
NSAIDs 98 73
Codeine 7 5
Dihydrocodeine 42 31
Tramadol 91 67
Morphine 129 96
Fentanyl 105 78
Buprenorphine 41 30
Methadone 5 3,7
Oxycodone 1 0,74
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Over a quarter of the respondents (27.4%) indi-
cated the answer “15 to 30 minutes”, and about 
5 percentage points less (23%) chose the answer 
“up to 5 minutes.” 3 doctors (2.22%) declared that 
they were not able to determine the time for the 
breakthrough pain to reach maximum intensity in 
their patients (Table 2). More than a half of the 
participating physicians (56.3%) reported the av-
erage duration of episodes of breakthrough pain 
as lasting for 15–30 minutes. Approximately 1/6 of 
respondents indicated “5–15 minutes” and “more 
than 30 minutes” (17.8% and 15.6%, respectively). 
Less than 3% of the respondents declared that they 
were not able to determine the average duration of 
episodes of breakthrough pain in their patients (Table 
3). Almost all the physicians (97.78%) declared the 
use of medication to control breakthrough pain. 
Only two people stated that they did not use such 
treatment, and one respondent did not answer 
this question. While answering the question regard-
ing the active ingredients used in the treatment of 
breakthrough pain, the vast majority of respond-
ents reported morphine (96.3%). Half of the physi-
cians (51.1%) declared that they used non-steroidal 
anti-inflammatory drugs, 40% — acetaminophen, 
and almost 30% — tramadol (Table 4).
Discussion
Breakthrough pain is defined as a transient exac-
erbation of pain, which can occur either spontane-
ously or under the influence of a specific stimulus, 
predictable or unpredictable, despite relatively stable 
and well-controlled background pain. Despite its in-
herently self-limiting nature, breakthrough pain (BtP) 
can be a huge problem and a physical, psychological 
and economic burden for patients suffering from 
cancer and cancer pain, as well as their families and 
people who provide care and treatment to these 
patients [3]. Appropriate and successful treatment of 
BtP may require a combination of non-pharmacolog-
ical and pharmacological treatment strategies. The 
most popular form of pharmacotherapy is the use of 
analgesic drugs called rescue medications. The ideal 
rescue medication should be characterized by a short 
Table 2. Number of BtP episodes and average time for BtP to reach maximum intensity
Number of BtP 
episodes
Number of 
physicians
% of physicians Avg. time for 
BtP to reach 
max. intensity
Number of 
physicians
% of physicians
1 8 5,93 0–5 min 31 22,96
2 58 42,96 5–15 min 62 45,93
3 51 37,78 15–30 min 37 27,41
4 10 7,41 > 30 min 0 0
> 4 4 2,96 Unable to 
determine
3 2,22
No answer 4 2,96 No answer 2 1,48
Sum 135 100 Sum 135 100
Table 3. Average duration of BtP episodes
Average duration of 
BtP episodes
Number of 
physicians
% of 
physicians
0–5 min 8 5,93
5–15 min 24 17,78
15–30 min 76 56,30
> 30 min 21 15,56
Unable to determine 4 2,96
No answer 2 1,48
Sum 135 100
Table 4. Drugs prescribed by physicians to control 
BtP episodes (more than one answer was possible) 
Analgesic used Number of 
answers
% of 
answers
Paracetamol 54 40
NSAIDs 69 51,11
Codeine 10 7,41
Dihydrocodeine 0 0
Tramadol 40 29,63
Morphine 130 96,3
Fentanyl 10 7,41
Buprenorphine 5 3,7
Methadone 1 0,74
Oxycodone 0 0
Other 6 4,44
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time to the onset of action, good efficacy, relatively 
short duration of action, and a good safety profile 
[4]. The drug should be administered before or short-
ly after the onset of a breakthrough pain episode. It 
has been demonstrated that the effective treatment 
of breakthrough pain can significantly improve the 
quality of life of patients [3–5]. Despite the fact that 
a number of publications extensively describing 
the pathophysiology, epidemiology, diagnosis, and 
treatment of breakthrough pain, it seems that there 
is still a large gap between this knowledge and daily 
practice, even in such specialized centers as palliative 
care units and pain clinics.
The purpose of this study was to assess the knowl-
edge of specialists working in outpatient palliative 
care and pain management clinics in Poland on the 
diagnosis and treatment of episodes of BtP. 135 
doctors decided to participate in the survey and all 
of them returned completed questionnaires. As can 
be seen from the questionnaires, the vast major-
ity of physicians (98.52%) diagnosed episodes of 
breakthrough pain in their patients with cancer 
pain. Moreover, knowledge of the nature of these 
episodes is very detailed. Doctors diagnose and have 
knowledge of the neurophysiological nature of BtP, 
the time it takes for the pain to rise in intensity, 
and its duration. The data obtained correlates with 
the literature data concerning the characteristics, 
to include qualitative ones, of breakthrough pain 
episodes [6–8]. Most physicians recognize BtP and 
the vast majority of them recommend pharmaco-
therapy to their patients (97.78% of respondents), 
mainly using morphine preparations (96.3%). These 
declarations are consistent with the results obtained 
in studies of breakthrough pain in patients treated 
in cancer centers in UK. Out of 87 patients suffering 
from BtP, 81 were prescribed opioid rescue medi-
cation [5]. There is still no answer to the question 
of how patients comply with the recommenda-
tions and whether they use the prescribed medica-
tion in the event of subsequent episodes of break-
through pain. British studies have shown that most 
patients take drugs much less frequently than the 
number of BtP episodes they declared would require 
[5]. The results of experiments performed by Italian 
researchers were different. One study showed that 
in 59.2% of cases, breakthrough pain was treated 
with additional doses of opioids, in 19.5% cases with 
non-steroidal anti-inflammatory drugs, and 21.3% of 
patients were not offered any additional treatment 
[9]. Interestingly, in terms of quantity of opioids used 
per capita, Poland, like Italy, occupies one of the last 
places in Europe. Meanwhile, the declared treat-
ment of cancer breakthrough pain episodes is more 
typical of countries with well-established opioid 
consumption (like the UK) [9, 10]. It is difficult to 
draw conclusions concerning the treatment of the 
entire population of patients with cancer pain in 
Poland; however, it can be stated that the special-
ists working in the outpatients’ clinics (palliative care 
and pain management) are very well prepared to 
diagnose and treat BtP. While analyzing the whole 
issue, some concerns remain regarding the declara-
tion that NSAIDs and acetaminophen were used in 
the treatment of BtP (such responses were given by 
51.1% and 40% of respondents, respectively). Un-
fortunately, the survey did not include a question on 
whether these drugs were used as adjunctive therapy 
in combination with an opioid or as a stand-alone 
treatment option.
Another issue is the lack (at the time of the sur-
vey) of alternatives available to the patient regarding 
the “rescue” oral opioid formulations in the form of 
transmucosal fentanyl in Poland. The pharmacoki-
netic profile of transmucosal preparations is different 
from oral medications, and can be a very good ad-
dition to the therapeutic options available, allowing 
the physician the right “fit” for the treatment of 
diagnosed episodes of breakthrough pain [11, 12].
In conclusion, studies confirm that doctors work-
ing in outpatient palliative care and pain manage-
ment units have essential theoretical knowledge and 
are well pre pared for the diagnosis and treatment of 
breakthrough pain episodes. The results presented 
above should be notwithstanding considered as pre-
liminary, and some issues (especially on pharmaco-
therapy) should be deepened in the future to get 
a clearer picture of the Polish practice of treating 
cancer BtP, particularly in relation to the greater 
availability of drugs that are likely to be used.
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